| 12.85 -0.3 (-2.28%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.82 |
1-year : | 16.43 |
| Resists | First : | 13.54 |
Second : | 14.06 |
| Pivot price | 13.56 |
|||
| Supports | First : | 12.69 |
Second : | 10.56 |
| MAs | MA(5) : | 13.32 |
MA(20) : | 13.54 |
| MA(100) : | 14.12 |
MA(250) : | 16.25 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 37.6 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 20.03 | Low : | 12.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDWD ] has closed below the lower bollinger band by 9.3%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.32 - 13.44 | 13.44 - 13.52 |
| Low: | 12.54 - 12.7 | 12.7 - 12.8 |
| Close: | 12.66 - 12.93 | 12.93 - 13.09 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Mon, 28 Sep 2026
Weekly Recap: DoD funding for NexoBrid and VALUE Phase III reassessment - TradingView
Tue, 22 Sep 2026
MediWound Awarded Additional $3.3 Million from U.S. - GlobeNewswire
Tue, 22 Sep 2026
A $21.8M program is developing burn care that can stay at room temperature - Stock Titan
Wed, 02 Sep 2026
Director of MediWound (NASDAQ: MDWD) trades shares via spouse - Stock Titan
Tue, 25 Aug 2026
New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq - Benzinga
Sun, 16 Aug 2026
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 15.9 (%) |
| Held by Institutions | 56 (%) |
| Shares Short | 1,590 (K) |
| Shares Short P.Month | 1,620 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.75 |
| Profit Margin | -170.2 % |
| Operating Margin | -305.9 % |
| Return on Assets (ttm) | -28.6 % |
| Return on Equity (ttm) | -72.4 % |
| Qtrly Rev. Growth | -45.8 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.91 |
| EBITDA (p.s.) | -2.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -5.95 |
| PEG Ratio | 0 |
| Price to Book value | 4.65 |
| Price to Sales | 13.98 |
| Price to Cash Flow | -7.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|